For patients with ACS undergoing DES implantation, de-escalating DAPT to P2Y12 inhibitor monotherapy is associated with lower bleeding risk.

A deescalation strategy involving switching from ticagrelor to clopidogrel in patients with acute myocardial infarction (AMI) ...

More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

We know from TWILIGHT that ticagrelor monotherapy after an initial 3 months of DAPT also seems to be an acceptable strategy. However, in the THEMIS-PCI trial comparing aspirin/ticagrelor with ...

Aspirin improves clinical outcome in all cardiovascular ... The new P2Y 12 antagonists, prasugrel and ticagrelor, are characterized by more potent antiplatelet effects and reduce recurrent ...

The results of PLATO (A Study of Platelet Inhibition and Patient Outcomes) 1 provide a major advance in our understanding of ADP receptor inhibition with the novel agent ticagrelor. When compared ...

Ticagrelor has saved the lives of thousands of heart attack ... Blood clots had only recently been discovered as the cause and aspirin became the standard treatment for preventing further clots.

The filing was based on results from the phase 3 THALES trial, which showed aspirin plus Brilinta 90 mg used twice daily for 30 days resulted in a statistically significant and clinically ...

BMI Shapes DAPT De-escalation After Primary PCI De-escalating dual antiplatelet therapy from from aspirin plus ticagrelor to aspirin plus clopidogrel after primary percutaneous coronary ...